Exercise of Options and Total Voting Rights

Intelligent Ultrasound Group PLC

16 August 2024

 

16 August 2024

Intelligent Ultrasound Group plc

("Intelligent Ultrasound" or the "Group" or the "Company")

Exercise of share options and change to total voting rights

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces that it has issued, conditional on admission, 170,000 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the exercise of share options.

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue and application has been made for the new Ordinary Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). Admission is expected to occur, and dealings in the new Ordinary Shares commence, at 8:00 a.m. on 19 August 2024.

Total Voting Rights

Following Admission, the Company will have 327,039,921 Ordinary Shares in issue. This figure of 327,039,921 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

For further information, please contact:

Intelligent Ultrasound Group plc	www.intelligentultrasound.com
Stuart Gall, CEO	Tel: [phone]
Helen Jones, CFO
Cavendish Capital Markets Limited (Nominated advisor and broker)
Giles Balleny / Dan Hodkinson (Corporate Finance) Nigel Birks (ECM) Dale Bellis (Sales)	Tel: [phone]

TB Cardew - PR Advisors  Ed Orlebar	[e-mail] Tel: [phone]
Allison Connolly	Tel: [phone]
Emma Pascoe-Watson	Tel: [phone]
Jessica Pilling	Tel: [phone]

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

Simulation

Real-time hi-fidelity ultrasound education and training through simulation.  Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,700 simulators have been sold to over 800 medical institutions around the world.

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE HealthCare's SonoLyst software that is incorporated in their Voluson Expert and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB. 

www.intelligentultrasound.com

NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the FDA but is not available for sale in any other territory requiring government approval for this type of product.

 

END